What to Expect From UnitedHealth Earnings
UnitedHealth Group is scheduled to report its third-quarter financial results Thursday before the markets open.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 242Axsome Therapeutics Files for IPO
Axsome Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Can-Fite Prepares for Secondary Offering
Can-Fite BioPharma announced that it has entered into definitive agreements with existing institutional investors in regard to a secondary offering.
What Analysts Have to Say About Nabriva After Quiet Period
Nabriva Therapeutics entered the market in mid-September, and now the quiet period has passed, allowing the underwriters can make calls.
Dimension Therapeutics Sets Terms for IPO
Dimension Therapeutics expects to offer 5.5 million shares within the price range of $14 to $16 in an IPO valued up to $101.2 million.
Johnson & Johnson Raises Forecast, Adds $10 Billion Buyback Plan
Johnson & Johnson reported mixed third-quarter 2015 results before markets opened Tuesday morning.
Aetna Seen Having Solid Upside in Independent Research Report
ThinkstockAetna Inc. (NYSE: AET) may be worth quite a bit more than its current price, and that might be the case with or without its merger with Humana Inc. (NYSE: HUM). That is the…
What to Expect From Johnson & Johnson Earnings
Johnson & Johnson is scheduled to report its third-quarter financial results before the markets open on Tuesday.
Can-Fite Biopharma Does It Again With Orphan Drug Designation
Can-Fite Biopharma announced that its oncology drug candidate has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
Will Theravance Succeed in Staph and MRSA?
Theravance announced on Monday that Vibativ demonstrated positive clinical outcomes for patients with staphylococcus aureus (S. aureus) bacteremia and methicillin-resistant S. aureus (MRSA) osteomyelitis
Eli Lilly Stumbles on Discontinued Drug Trial
Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.
Short Sellers Become More Selective on Major Pharma
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Short Sellers Increase Bets in Major Biotechs
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Why Cholesterol and Alzheimer’s Could Drive Eli Lilly Shares Much Higher
Credit Suisse sees solid upside in this company Eli Lilly as the result of a strong pipeline, with its Alzheimer's candidate as a potential blockbuster.
UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.